Some of the most important healthcare companies begin by addressing a problem the industry has learned to tolerate.

Raj Malhotra, founder and CEO of Smartweave, believes connective tissue repair has such a problem. Surgeons have long known that all patients do not heal in the same way. Inflammation, tissue quality, age, medical history, and biomechanics can all shape recovery, even when two patients undergo similar procedures with the same type of implant.

Yet the implant itself is usually designed around a broad patient population. The individual differences that influence healing outcomes are often addressed after treatment rather than incorporated into the design process from the beginning.

For Malhotra, that was more than a clinical limitation. It was a structural flaw in how regenerative therapies were being developed.

Building More Than Another Device

Malhotra has built healthcare technology companies before and has worked on surgical technologies and methods across global markets. When he began examining connective tissue repair more closely, he concluded that developing another implant would not solve the deeper problem if the underlying design process remained unchanged.

Smartweave was built around a different question: What would happen if regenerative therapies were designed using the patient’s biology before treatment decisions were made?

The company’s SMARTS platform, short for Specific Matrix Assisted Regenerative Tissugenic Scaffold, combines three capabilities.The system first evaluates a patient’s physiological profile to understand any background conditions such as inflammation and risk for complications. This information is combined with anatomical imaging to simulate a digital twin model that can be used to formulate and test personalized solutions. This digital twin informs a formulation and design that matches regenerative components, including biocoatings, hydrogels, and other regenerative agents, to the characteristics of that individual patient.

“The biology is already there,” Malhotra says. “Every patient carries the blueprint for their own repair. Smartweave was built to read it.”

Choosing a Platform Strategy

That idea led Malhotra to build Smartweave as a platform company rather than a single-product business.

The same underlying system supports several clinical applications. HeraWeave is being developed for pelvic floor repair, OrthoWeave for tendon and ACL restoration, CardioWeave for personalized cardiac valve replacement, and DentaWeave for periodontal regeneration.

Each product addresses a different area of medicine, but the business logic remains consistent. Smartweave is creating one technological foundation that can be applied across multiple connective tissue markets.

That structure also supports a dual revenue model. Through Smartweave Inside, the company licenses its intellectual property to other businesses while developing its own products for direct commercialization. Smartweave reports that it has already generated $1.6 million in licensing revenue, giving the company an early commercial foundation while it continues through the longer development and regulatory process required for medical devices.

Establishing Credibility Early

For an early-stage healthcare company, ambition matters less than whether the science, team, and development pathway can withstand scrutiny.

Smartweave has received early recognition from organizations with experience in digital modeling and healthcare innovation. Dassault Systèmes selected the company as one of three startups worldwide to help launch its digital twin program. Smartweave was also selected by Tech4Eva, an EPFL-affiliated women’s health accelerator, from more than 300 global ventures.

Its advisory team includes specialists from Stanford Medicine, Baylor Scott & White, Cedars-Sinai, and the University of Puerto Rico, with expertise spanning urogynecology, cardiothoracic surgery, tendon regeneration, and biomedical engineering.

The company has also reported encouraging preclinical results in animal models involving pelvic tissue regeneration and tendon repair. Those findings do not indicate human outcomes, and Smartweave has not received FDA clearance or approval for any product. The company is currently pursuing a Class II medical device pathway, with its first planned commercial milestone targeted for 2027.

Rebuilding the Starting Point

Malhotra’s central decision was not to improve one implant. It was to reconsider how regenerative products should be designed before an implant ever reaches the operating room.

That distinction has shaped Smartweave’s technology, business model, advisory network, and commercialization strategy. It has also allowed the company to pursue several clinical markets without losing sight of the same underlying problem: patients heal differently, but medical products are still largely designed as though they do not.

For other founders, the lesson is less about regenerative medicine than about where meaningful opportunities often appear. Industries frequently develop workarounds around long-standing limitations. The harder task is recognizing when the workaround has become the obstacle and building a company capable of changing the process itself.